Assessment of response to therapy in hepatocellular carcinoma

References

• World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
   PubMed Web of Science ®Google Scholar
• Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143–52.
   PubMed Web of Science ®Google Scholar
• McIntire KR, Vogel CL, Primack A, Waldmann TA, Kyalwazi SK. Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer. 1976;37: 677–83.
   PubMed Web of Science ®Google Scholar
• Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446–52.
   PubMed Web of Science ®Google Scholar
• Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734–42.
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101–7.
   PubMed Web of Science ®Google Scholar
• Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, Lee do Y, et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371–9.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst. 1980;64: 1329–32.
   PubMed Web of Science ®Google Scholar
• Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, Hilzenrat N, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol. 2007;21:39–45.
   PubMedGoogle Scholar
• Sherman M. The resurrection of alphafetoprotein. J Hepatol. 2010; 52:939–40.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein < 20 ng/mL. Cancer Sci. 2011;102:1025–31.
   PubMed Web of Science ®Google Scholar
• Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998;82:1643–8.
   PubMed Web of Science ®Google Scholar
• Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010;16:4410–15.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013;58:169–77.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.
   PubMed Web of Science ®Google Scholar
• Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, et al. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford). 2014; 16:327–35.
   PubMed Web of Science ®Google Scholar
• Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212–18.
   Web of Science ®Google Scholar
• Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol. 2013;25:620–7.
   PubMed Web of Science ®Google Scholar
• Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181–7.
   PubMed Web of Science ®Google Scholar
• Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16–22.
   PubMed Web of Science ®Google Scholar
• Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826–34.
   PubMed Web of Science ®Google Scholar
• Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, et al. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013;6:51.
   PubMed Web of Science ®Google Scholar
• Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;181:708–10.
   PubMed Web of Science ®Google Scholar
• Eccles C, Haider MA, Dawson LA. In reply to letter to the editor by Dr Willems et al. re: Eccles et al. Change in diffusion weighted MRI during liver cancer radiotherapy: Preliminary observations. Acta Oncol. 2010;49:256–7.
   PubMed Web of Science ®Google Scholar
• Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol. 2009;48:1034–43.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int. 2014;34:305–12.
   PubMed Web of Science ®Google Scholar
• Duke E, Deng J, Ibrahim SM, Lewandowski RJ, Ryu RK, Sato KT, et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol. 2010;21:515–21.
   PubMed Web of Science ®Google Scholar
• Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 +/− sorafenib. Hepatology. 2013;58:1655–66.
   PubMed Web of Science ®Google Scholar
• Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19:1108–18.
   PubMed Web of Science ®Google Scholar
• Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria—selection parameter for liver transplantation. Radiology. 2010;255:289–300.
   PubMed Web of Science ®Google Scholar
• Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062–9.
   PubMed Web of Science ®Google Scholar